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Abstract  
Oral squamous cell carcinoma (OSCC) is associated with substantial mortality and morbidity.  
To identify potential biomarkers for early detection of invasive OSCC, we compared gene 
expression of incident primary OSCC, oral dysplasia, and clinically normal oral tissue from 
surgical patients without head and neck cancer or pre-neoplastic oral lesions (controls), using 
Affymetrix U133 2.0 Plus arrays. We identified 131 differentially expressed probe sets using a 
training set of 119 OSCC patients and 35 controls. Forward and stepwise logistic regression 
analyses identified 10 successive combinations of genes which expression differentiated OSCC 
from controls. The best model included LAMC2, encoding laminin gamma 2 chain, and 
COL4A1, encoding collagen, type IV, alpha 1 chain. Subsequent modeling without these two 
markers showed that COL1A1, encoding collagen, type I, alpha 1 chain, and PADI1, encoding 
peptidyl arginine deiminase, type 1, also can distinguish OSCC from controls. We validated 
these two models using an internal independent testing set of 48 invasive OSCC and 10 controls 
and an external testing set of 42 head and neck squamous cell carcinoma (HNSCC) cases and 14 
controls (GEO GSE6791), with sensitivity and specificity above 95%. These two models were 
also able to distinguish dysplasia (n=17) from control (n=35) tissue. Differential expression of 
these four genes was confirmed by qRT-PCR. If confirmed in larger studies, the proposed 
models may hold promise for monitoring local recurrence at surgical margins and the 
development of second primary oral cancer in OSCC patients. 
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Introduction 
    Squamous cell carcinoma of the oral cavity and oropharynx (OSCC) is of considerable public 
health significance. In the United States, it is estimated that nearly 35,000 new OSCC cases were 
diagnosed in 2007, and approximately 7,550 OSCC deaths are estimated to occur 
(http://www.cancer.org). World-wide, OSCC is the 6th most common caner, with an estimated 
405,000 new cases and 211,000 deaths annually (http://www-dep.iarc.fr ) (1). Despite 
considerable advances in surgical techniques, and the use of adjuvant treatment modalities, the 5-
year survival for OSCC patients is about 60% for U.S. Whites and 36% for U.S. Blacks 
(http://www.cancer.org). In addition, OSCC is often associated with loss of eating and speech 
function, disfigurement and psychological distress.  
As much as 20% of oral dysplasia undergoes malignant transformation to OSCC (2, 3). 
Among OSCC patients with histologic positive tumor margins, the likelihood of local recurrence 
is as high as 70 to 80%. Even among patients with negative margins, the reported probability of 
recurrence is 30-40% (4), suggesting histologic examination alone is inadequate in predicting 
recurrence (4-6). There is an urgent need to identify better ways to predict which patients with 
dysplastic precursor lesions will develop OSCC and which patients treated for OSCC will 
develop recurrence, so that high-risk patients can be selected for more rigorous treatment and 
follow-up. We hypothesize that patients who develop local recurrence and/or second primary 
oral tumors are those whose surgical margins or uninvolved buccal mucosa harbor molecular 
changes that are found in oral dysplasia or invasive OSCC.   In this report, we present results on 
the differential gene expression profiles between OSCC, oral dysplasia and normal controls and 
several predictive models t that 1) can potentially be easily used to test biopsies of histologically 
normal surgical margins and clinically normal oral mucosa of OSCC patients for the prediction 
 
Genetic expression profiles of squamous oral cancer  
of local recurrence and/or second primary oral cancer; and 2) enhance our understanding of the 
underlying biological mechanisms of this disease.    
 
 
Materials and Methods 
 
    Study Population. Eligible cases were patients with their first primary OSCC scheduled for 
surgical resection or biopsy between December 1, 2003 and April 17, 2007 at the University of 
Washington Medical Center, Harborview Medical Center and the VA Puget Sound Health Care 
System in Seattle, Washington. We also sought to enroll patients with diagnosed dysplastic 
lesions at these medical centers during the same period. Eligible controls were patients who had 
tonsillectomy or oral surgery for treatment of diseases other than cancer, such as obstructive 
sleep apnea, at the same institutions and during the same time periods in which the OSCC cases 
were treated. All three groups of patients were 18 years of age or older and capable of 
communicating in English.  
    Among 244 eligible OSCC patients, we were able to consent 187 patients. Of these, 171 
patients gave permission for medical chart abstraction and provided sufficient tissue to yield 
GeneChip arrays results that passed our quality control (QC) criteria (see below). Among 21 
eligible dysplasia cases, 15 provided consent for the study. Of these, 11 patients had GeneChip 
results passed QC checks. One dysplasia patient provided dysplasia tissues from two different 
sites. One OSCC patient provided one piece of cancer tissue and one piece of dysplasia tissue, 
and assay results from this latter tissue were grouped with the dysplasia patients. Four of the 
eligible patients originally believed to have OSCC had a final pathology report of dysplasia, and 
these were included in the dysplasia group, and not in the OSCC group for analyses. In total, 17 
dysplasia samples were used for analyses. During the case recruitment period, 47 of 55 eligible 
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controls consented to participate. Samples from two controls failed QC checks leaving 45 for 
analyses. 
    Each participant was interviewed using a structured questionnaire regarding demographic, 
medical, functional, quality of life, and lifestyle history, including tobacco and alcohol use. 
Tumor characteristics (site, stage) were obtained from medical records. This study was 
conducted with written informed consent and Institutional Review Office approvals.  
    Tissue Collection. Tumor tissue was obtained at time of resection or biopsy from patients 
with a primary OSCC, or dysplasia. Clinically normal tissue from the oral cavity or oropharynx 
was obtained from controls. For the small number of controls (~30%) with tonsillitis or tonsil 
hypertrophy, only mucosa tissue from tonsillar pillar was obtained to avoid potential influence of 
inflammation on the results.  Immediately after surgical removal, the tissue was immersed in 
RNALater (Applied Biosystems, Inc. Foster City, CA) for a minimum of 12 hours at 4 ° C 
before being transferred to long term storage at – 80 ° C prior to use.  
    DNA Microarray. Total RNA was extracted using a TRIzol method (Invitrogen, Carlsbad, 
CA), purified with an RNeasy mini kit (Qiagen, Valencia, CA), processed using a GeneChip 
Expression 3’-Amplification Reagents Kit (Affymetrix), and interrogated with an Affymetrix 
U133 2.0 Plus GeneChip arrays (see Supplemental Material for experimental details).  
    QC Checks of GeneChip Results. We conducted two rounds of QC checks to evaluate 
whether to include results from each of the GeneChips. In the first round, recommendations 
made by Affymetrix 
(http://www.affymetrix.com/support/downloads/manuals/data_analysis_fundamentals_manual.p
df) were followed. In the second round, we used the “affyQCReport” and “affyPLM” software in 
the Bioconductor package (http://www.bioconductor.org) to search for poor quality chips. In 
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total, 172 chips from 165 patients (119 OSCC patients, 35 controls and 11 dysplasia patients 
passed two rounds of QC evaluation. 
Preprocessing and Probe Set Filtering. For those GeneChip arrays that passed QC checks, we 
used gcRMA algorithm from Bioconductor to extract gene expression values and perform 
normalization. Next, to limit the multiple testing penalty in the statistical testing step, we 
eliminated the probe sets that either showed no variation across the samples being compared 
(inter quartile range (IQR) of expression levels less than 0.1 on log2 scale) or were expressed at 
very low magnitude (any probe set in which the maximum expression value for that probe set in 
any of the samples was less than 3 on log2 scale). After these criteria were applied, ~21,000 
probe sets remained for differential expression analyses.  
    Differential Gene Expression Analyses. To examine differential gene expression and to 
build prediction models, we divided our samples into a training set of 119 OSCC cases and 35 
controls and a testing set of 48 OSCC cases and 10 controls. The division of study subjects into 
training and testing sets was based on the calendar date that patients were enrolled into the study. 
Gene expression values from gcRMA were analyzed using a regression-based, estimating 
equations, approach implemented in GenePlus software (http://www.enodar.com/) (7, 8). Age 
and sex were included as covariates in the analyses of the training set. To control type I errors, 
we declared a particular group of genes either “upregulated/overexpressed” or 
“downregulated/underexpressed” based on a fixed number of false discoveries (NFD), i.e., the 
number of false discoveries in a list of discovered genes is controlled at the pre-specified NFD 
(9).  The choice of NFD, with an appropriate account for the number of genes under 
investigation (J), dictates the threshold for individual gene-specific p-values as NFD/J. Using 
NFD<1 as a statistical testing criterion, we identified 7,604 probe sets as being differentially 
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expressed between controls and cases. To build predictive models and substantially reduce the 
number of comparisons, we further narrowed this list of candidate probe sets using the following 
criteria that  retained only those probe sets that showed large difference in signal intensity 
between cases and controls: 1) absolute Z-score >6 in the differential gene expression analysis, 
implying exceptionally high statistical significance; 2) a 1.5-fold or greater difference in gene 
expression between controls and cases. A large difference is needed to provide good predictive 
ability. And, 3) the mean expression value summarized by Affymetrix Microarray Suite 5.0 
across samples >300 (with the scaled mean expression value of 1000). Probe sets with such 
expression values are more likely to be suitable for validation by alternative methodologies such 
as qRT-PCR. A total of 131 probe sets were selected by these three criteria.  
    Biological Pathway Analyses and Hierarchical Clustering of Differentially Expressed 
Genes. We analyzed the 7,604 differentially expressed probe sets between OSCC and controls 
using Ingenuity Pathway Analysis 4.0 (Ingenuity®Systems, www.Ingenuity.com) and performed 
hierarchical clustering of all the samples based on their expression of the 131 probe sets using 
Affymetrix GeneSpring software GX7.3.1. 
    Prediction Models. The selected 131 probe sets were analyzed using both forward and hybrid 
of forward-backward logistic regression procedures (SAS PROC LOGISTIC). For the one OSCC 
case with results from 5 replicate tissues and one control with results from duplicate tissues, the 
respective average of the replicate results was used. In the forward stepwise selection, probe sets 
were processed in the logistic regression model: one probe set at a time until no probe set could 
be added based on the significance level of 0.01. When the hybrid stepwise selection was 
adopted, the probe set with the smallest p-values and p< 0.01 entered first, and significance 
levels for other selected probe sets were evaluated for possible removal if their p-values were 
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greater than 0.05 in the current model. We compared the performance of the two models (results 
from the forward and hybrid stepwise procedures) using receiver operating characteristic (ROC) 
curves. An ROC curve is a plot of true positive rate (sensitivity) on the Y-axis against false 
positive rate (1-specificity) on the X-axis for each possible value (in our case, the logistic score 
for each individual for a given model) representing a positive test,. A model with perfect 
discrimination between cases from controls will have a ROC curve that passes through the upper 
left corner, with 100% sensitivity, 100% specificity, and area under the curve (AUC) of 1. An 
AUC=0.5 represents a test that is no better than chance at discriminating between cases and 
controls (10-12). 
    Validating Prediction Models. We validated the selected prediction models with our own 
independent validation dataset and an external validation dataset from GEO (Gene Expression 
Omnibus, www.ncbi.nlm.nih.gov/geo, GSE6791 containing 42 HNSCC cases and 14 controls) 
(13). CEL files from these datasets were extracted using gcRMA algorithm. ROC curves were 
drawn by applying the expression results to the prediction models. 
    Comparison of Gene Expression of the Prediction Models in Different Tissues to Test the 
Specificity of the Models for OSCC. We downloaded gene expression data from GEO 
GSE6791 for normal and tumor cervical tissue samples and GSE6044 for normal and tumor lung 
samples. We chose these datasets because: 1) they were generated using the same Affymetrix 
U133 GeneChip platform as ours, facilitating testing the tissue specificity of our predictive 
models; and 2) OSCC share some of the same risk factors as cervical cancer and lung cancer; 
Human Papillomavirus in the case of cervical cancer and cigarette smoking in the case of both 
cervical and lung cancer. We extracted gene expression values using gcRMA and, for each tissue 
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type, calculated the scores for each of the prediction models derived from analysis of our training 
dataset. 
    Comparison of Gene Expression Profiles in Controls, Dysplastic Lesions and Invasive 
Cancer. While the expression of some genes may be continuously increasing or decreasing from 
the moment normal oral tissue begins its oncogenic process, it is also possible that some genes 
get turned on or off during the conversion from dysplasia to invasive cancer. To explore this 
hypothesis and to identify genes that may be specific for the conversion of dysplasia to OSCC, 
we compared gene expressions of invasive cancer (n=167) with those of normal oral tissue (from 
45 controls) and dysplastic lesions (n=17) combined using ~21,000 filtered probe sets. From 
those probe sets that were differentially expressed between OSCC samples and the combination 
of controls and dysplastic lesions, we further excluded those that were differentially expressed 
between controls and dysplasia using NFD=1 (see Supplemental Material for schematic 
representation of the method for selecting the differentially expressed genes specific to OSCC). 
The resulting gene list contained the genes that were up- or downregulated in OSCC but not in 
dysplasia. Conversely, we combined dysplastic lesions and OSCC samples and compared them 
with the controls. For those probe sets showing differential expression, we excluded the genes 
that were also differentially expressed between dysplasia and cancer. The resulting gene list 
contained genes that showed up- or downregulation (relative to normal tissue) as early as 
dysplasia. 
    Validation of Gene Expression of LAMC2, COL4A1, COL1A1, and PADI1 by qRT-PCR. 
qRT-PCR was performed in triplicate on a subset of 30 OSCC cases and 30 controls using a 
QuantiTect SYBR Green RT-PCR kit (Qiagen, Valencia, CA) and bioinformatically validated 
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QuantiTect primers (Qiagen, Valencia, CA) on a 7900HT Sequence Detection System (ABI, 




    The cases in both the training and testing sets tended to be older than the controls. Compared 
to controls, cases were more likely to be male, white, and current smokers. Approximately two 
thirds of the cases had AJCC stage III or IV disease with about 50% of the cases presenting with 
metastasis to the neck. Oral cavity tumors accounted for 74% and 60% and oropharyngeal 
tumors account for 26% and 40% of the OSCC cases in the training and testing sets, respectively. 
Most of the dysplasia subjects were White males whose lesions were located in the oral cavity 
(see Supplemental Table 1). 
    Results obtained with the Ingenuity Pathway Analyses tool showed that the JAK/STAT 
signaling pathway and the IFG-γ signaling pathway were the top two biological pathways 
associated with the differentially expressed genes. Figure 1 shows genes that were up- or 
downregulated in these two pathways in our training dataset. 
    Table 1 lists the 131 probe sets differentially expressed between OSCC and controls based on 
the criteria described in the Methods. Among the 131 probe sets were transforming growth factor 
TGFB1, cell signaling molecule STAT1, immune markers IL1β, chemokines CXCL2, 3, 9, and 
genes encoding for extracellular matrix proteins and collagens that have previously been shown 
to be involved in the motility and invasion of tumor cells. Hierarchical clustering of gene 
expression using the 131 probe sets showed that invasive OSCC and normal control formed two 
main clusters. About half the dysplasia tissues clustered with OSCC samples and half clustered 
with the controls. Compared to invasive OSCC, oral dysplasia tissue appeared to have a set of 
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genes that were not yet upregulated and another set of genes that were not yet downregulated 
(see heat map in Supplemental Material). 
    Table 2 lists the top 10 models from the logistic regression analyses of the 131 probe sets in 
our training data set. The model with LAMC2 (probe set 207517_at, encoding laminin γ2) and 
COL4A1 (211980_at, encoding collagen type IV, α1) had the most discriminating power to 
separate OSCC from controls (AUC=0.99952). The power to distinguish OSCC from controls 
was very slightly reduced if expression of only one of these two probe sets was used 
(AUC=0.99424 with COL4A1 alone). After removing LAMC2 and COL4A1 from subsequent 
modeling, COL1A1 (202310_s_, encoding for collagen type I, α1) and PADI1 (220962_s_, 
encoding for peptidyl arginine deimminase type 1) emerged as the next set of markers that best 
separated OSCC from controls (AUC=0.99976).  
    When we applied the expression values from the testing datasets to the predictive models 
derived from our training dataset, the model with LAMC2 (probe set 207517_at) and COL4A1 
(211980_at) had the most discriminating power to separate OSCC from controls: AUC=0.997 in 
our independent testing set and AUC=0.976 in the external testing set (GEO GSE6791), 
respectively (Table 2). The model with COL1A1 and PADI1 also was strongly predictive 
(AUC=0.99167 in our testing set, and AUC=0.97789 in the external GEO GSE6791 data set 
(Table 2). Results on the testing of the other eight models against the internal and external 
datasets indicate that they also performed well in distinguishing OSCC from controls (Table 2). 
Results of qRT-PCR on LAMC2, COL4A1, COL1A1 and PADI1 confirmed the differential 
expression of these genes between OSCC and controls at the transcript level (Table 3). 
    We next examined whether the top two models that were particularly effective in 
discriminating OSCC from controls were specific to OSCC (or HNSCC) and not other epithelial 
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cancer types with overlapping risk factors. For each of these two predictive models, we 
compared the scores for cases and controls calculated from our testing dataset to the scores from 
the GEO HNSCC dataset (GSE6791) and from the GEO cervical cancer and lung cancer data 
sets (GSE6044) and their controls. The model containing LAMC2 and COL4A1 distinguished 
HNSCC from controls, but not cervical cancer nor lung cancer from their respective controls 
(Figure 2, top panel); COL1A1 and PADI1 also performed well for HNSCC and, to a lesser 
extent, for lung cancer, but not cervical cancer (Figure 2, bottom panel). Furthermore, our results 
showed that these two models could not only distinguish invasive cancer from controls, but also 
distinguish oral dysplasia from controls. The respective AUC was 0.98 for LAMC2 and COL4A1 
and 0.99477 for COL1A1 and PADI1. However, the effect we observed here for the model 
LAMC2 and COL4A1 was driven by COL4A1, suggesting COL4A1 up-regulation occurs earlier 
than LAMC2 up-regulation in oral carcinogenesis (data not shown). 
    Comparison of gene expressions of invasive cancer with those of normal oral tissue (from 
controls) and dysplasia combined using ~21,000 filtered probe sets, followed by elimination of 
those probe sets that were differentially expressed between dysplasia and controls, showed the 
differential expression of 6544 probe sets, including 3988 upregulated and 2666 downregulated 
probe sets in invasive OSCC. Table 4 lists among the 131 probe sets the 49 probe sets that may 
be specific for the conversion of oral dysplasia to OSCC. Sixty-seven probe sets that may be 
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    We have identified 131 probe sets, corresponding to 108 known genes, which are highly 
effective in distinguishing invasive OSCC and normal oral tissue, as well as a list of genes that 
might be involved in the transformation of normal oral tissue to dysplasia, and of oral dysplasia 
to invasive OSCC. Although prior studies, including our own, have described global changes in 
gene transcription that distinguish normal oral epithelium from carcinoma, there is considerable 
heterogeneity among the lists of genes that have been reported and, to our knowledge, few 
studies have produced a limited combinations of genes as in the current study with high 
sensitivity and specificity in distinguishing OSCC from normal oral tissue through rigorous 
statistical testing and validation with independent datasets, and none had provided prediction 
models (14). The current study provides prediction models that were generated using rigorous 
statistical analyses, and the differences in gene expression detected using microarray technology 
was validated by qRT-PCR, and by testing against independent internal and external genome-
wide gene expression datasets. The ultimate goal of our work has been to generate candidate markers 
that can be easily applied to the testing of biopsies or surgical margins to aid diagnosis and prognosis of 
OSCC. It is our hope that the signals we identify will be strong enough to use in a clinical test without 
resorting to the isolation of the tumor cells and stromal cells, knowing that both cell populations play 
important role in OSCC development and progression. Thus, we have deliberately choose not to use laser 
capture microdissection to isolate tumor cells for this investigation.  We believe that our current 
prediction models and the 131 genes that we identified warrant testing in subsequent studies for 
their utility in predicting local recurrence at surgical margins or the development of second 
primary cancer of OSCC patients, or for selective screening of individuals who are at high risk of 
OSCC. It is possible that histologically- negative margins harbor microscopic original tumor as 
residual disease. If so, the gene expression profile would more likely resemble that of the 
resected invasive OSCC, and measurement of one or more of the 131 genes we identified and 
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application of one of  our top models could potentially be of use for its detection.  For 
individuals who are at high risk of OSCC, their oral epithelium could contain cells that are 
molecularly abnormal and primed for the development of cancer. As such, the molecular profile 
might be more similar to that of a pre-neoplastic oral lesion than that of an invasive OSCC. The 
list of genes that we generated that distinguishes invasive OSCC from dysplasia and controls 
could potentially be used to gauge malignant potential of these molecular changes. Recently, p53 
and eIF4E have been evaluated to augment histologic assessment of surgical margins (4, 15). 
eIF4E expression, but not P53 mutation and overexpression, in histologically negative surgical 
margins was a significant predictor of recurrence and shorter disease-free survival of HNSCC 
patients (16-18).  
    In the current study, we found that the expressions of two pairs of genes (LAMC2 and 
COL4A1; COL1A1 and PADI1) were particularly effective in distinguishing OSCC from normal 
oral tissue in independent testing sets. The sensitivity and specificity were close to 100%. 
Because of the stringent criteria we applied to select candidate markers, it is expected that there 
are other probe sets among the 131 probe sets with a similar predictive property. We previously 
observed the differential expression of many of the 131 probe sets, including LAMC2, COL1A1 
and COL4A1 (19). Overexpression of laminin gamma 2 in HNSCC, particularly in the invasive 
front of tumors, has been reported by others (20, 21). A study by Pyeon et al (13) that used 
normal controls (n=14) and the same Affymetrix GeneChip arrays also found highly expressed 
LAMC2, COL4A1 and COL1A1 in OSCC (n=42), compared to controls. A study by Ziober et al 
(22), using Affymetrix U133 GeneChip arrays to compare gene expression of oral cavity tumors 
and paired adjacent clinically normal oral tissue from 13 patients, produced a list of 25 genes that 
showed 86-89% accuracy in distinguishing OSCC from controls in three small testing datasets 
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that contained 13, 18 and 5 tumor samples and even fewer controls. Only seven of the 25 probe 
sets, encoding for COL1A1, 4A1, 5A1, 5A2, microtubule, periostin and podoplanin, were among 
our list of 131 probe sets. Given the differences between their study and ours, i.e., sample size, 
tumor site, source of control samples, analytical methods and the sample size of the testing sets, 
the common observation of differential expression of collagen genes and genes involved in cell 
shape and movement underscores the potential importance of these genes in oral carcinogenesis. 
Another study of gene expression signature (23), involving comparison of oropharyngeal tumor 
samples from three patients with adjacent normal nonmalignant mucosa using a 9,350 EST 
cDNA array, reported differential expression of nine genes (23). Only periostin in their list was 
among our 131 top candidate markers. 
 Our results were adjusted for age and sex. Although life style characteristics, such as tobacco 
use and infection with Human Papillomavirus (HPV) play an important role in OSCC 
development, we did not observe any appreciable difference in gene expression on the genome-
wide level according to smoking status (former/current vs. never) or HPV status (positive vs. 
negative). Only when we examined oropharyngeal cancers alone, did we find differential gene 
expression between HPV-positive and HPV-negative tumors. The latter results have been 
submitted for review in a separate manuscript (Lohavanichbutr et al).  
   Laminin binds to Type IV collagen and to many cell types via cell surface laminin receptors 
(24). Following attachment to laminin in the basement membrane, tumor cells secrete 
collagenase IV that specifically breaks down type IV collagen thus facilitate cell spreading and 
migration (25). In addition, laminin fragments generated by post-translational proteolytic 
cleavage bind to cell surface integrins and other proteins to trigger and modulate cellular motility 
(26). Increased levels of laminin have been associated with a number of carcinoma (27-35). In 
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some of these studies, laminin was associated with tumor aggressiveness, metastasis and poor 
prognosis. Results from mouse models showed that tumor cells with high levels of laminin and 
low level of unoccupied laminin receptor are resistant to killing by natural cytotoxic T cells and 
are highly malignant (36) and that treatment with low concentrations of laminin receptor binding 
fragments of laminin blocked lung metastasis of hematologenously introduced tumor cells (37).  
A large number of unoccupied laminin receptors have been observed for breast and colon cancer 
cells (25); no similar reports have appeared on OSCC or HNSCC cells. Further studies of 
laminin and its receptors should be pursued for its role in OSCC etiology and progression. 
    The gene products of COL4A1 and COL4A2 are assembled into type IV collagen that form the 
scaffold of basement membrane integrating other extracellular molecules, including laminin, to 
produce a highly organized structural barrier. Collagen IV also plays an important role in the 
interaction of basement membrane with cells (38, 39). Immune cells, migrating endothelial cells 
and metastatic tumor cells have been reported to produce and tightly regulate type IV collagen-
specific collagenase (40-42). Degradation of Type IV collagen could compromise basement 
membrane integrity and facilitate tumor cell spreading and migration. It is possible that the 
observed overexpression of COL4A1 by our study and by Pyeon et al is the net result of 
overproduction and degradation. Whether COL4A1 contributes to OSCC development is 
unknown and awaits investigation.  
    Peptidyl arginine deiminases (EC 3.5.3.15) catalyze post-translational modification of proteins 
through conversion of arginine residues to citrullines. Although their physiological functions are 
not well understood, they have been implicated in the genesis of multiple sclerosis, rheumatoid 
arthritis, and psoriasis (43). The isoform peptidyl arginine deiminases type 1 (PADI1) is present 
in the keratinocytes of all layers of human epidermis. It has been reported that deimination of 
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filaggrin by PADI1 is necessary for epidermal barrier function and deimination of keratin K1 
may lead to ultrastructural changes of the extracellular matrix (43). We found the expression of 
PADI1 to be downregulated in both dysplasia and OSCC when compared to controls. If 
deimination of arginine residues of proteins in the keratinocytes of oral mucosa by PADI1 forms 
an epidermis barrier, downregulation of PADI1 may allow the growth, expansion and movement 
of tumor cells. Given the strength of our observation, it would be important to examine the 
function of PADI1 in cell lines and animal model systems.  
    Among the biological pathways we identified to be prominently involved in OSCC were the 
JAK/STAT and interferon gamma (IFN-γ) signaling pathways. A wide array of cytokines and 
growth factors, including EGFR, transmit signals through the JAK/STAT pathway (44, 45). 
EGFR overexpression has been reported in up to 90% of HNSCC tumors (46). Single modality 
therapeutics that target against EGFR, such as small molecule tyrosine kinase inhibitors, 
monoclonal antibodies, antisense therapy or immunotoxin conjugates, however, were only 
effective in 5-15% of patients with advanced HNSCC (47). These observations suggest that there 
are other proteins and pathways driving the growth of some of these tumors. To our knowledge, 
this is the first study to show a strong association between IFN- γ signaling pathway and OSCC. 
Interestingly, IFN- γ signaling also involves the JAK/STAT pathway (44, 48). It is unclear 
whether the upregulation of the IFN- γ pathway is intrinsic to the tumor cells or is due mainly to 
the immune cells present in the stroma. Further studies utilizing laser capture microdissection to 
address this question are warranted.  
    We identified a set of genes that are possibly involved in, and specific for, the malignant 
transformation of oral dysplasia into invasive OSCC. These genes include those that encode for 
proteins that are known for cell-matrix and cell-cell interaction, cellular migration or invasion, 
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such as LAMC2 and, SERPINE1 (PAI-1); for directed-cellular movement, such as CXCL2, 3, and 
9, as well as for immune function, such as IL1β and IFIT3. Due to the small number of dysplasia 
cases we studied, however, we were not able to separate the samples into a training set and a 
testing set. Another limitation is that the comparisons were made between dysplasia samples 
collected from the oral cavity and OSCC from both the oral cavity and oropharynx, and the 
controls from mucosa of oropharynx or tonsillar pillar. Thus, our results await confirmation or 
refutation by others. Kondoh et al (49) reported the differential expression of 27 genes between 
27 OSCC and 19 leukoplakia tissues based on their IntelliGene Human Expression cDNA array 
and qRT-PCR. Among those 27 genes, only LAMC2, IFIT3 and USP18 were on our list. The 
observed discrepancy is not surprising, given the large number of differences between the two 
studies: 1) Kondoh et al compared OSCC with leukoplakias, while we compared OSCC with 
dysplastic lesions; and 2) that study used microdissected samples to remove stroma while we did 
not, and they assayed the samples with a 16,600 probe set cDNA array, as opposed to our 
~50,000 probe set oligonucleotide array. Nonetheless, their study and ours show that LAMC2, 
IFIT3 and USP18 are worthy of further investigation as predictors of the development of OSCC 
among patients with oral dysplasia.  It is interesting to point out that, among our 131 probe sets, 
a large number of collagen genes were among the probe sets that may be associated with the 
conversion of oral tissue to dysplasia (Supplemental Table) and were absent among the probe 
sets that may be involved in the conversion of dysplasia to invasive OSCC (Table 4). These 
observations suggest that collagen genes may play an important role early in the oral 
carcinogenesis process.  
    Although our sample size is substantially larger than other microarray articles published on 
HNSCC, it is nonetheless very small when compared to the number of genome-wide 
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comparisons we were making. Furthermore, the sample sizes of the internal and external testing 
sets that we used to test the predictive power of our proposed models were also small. Although 
we validated the differential expressions of the four markers in the top two models, whether 
these four markers will continue to exhibit the greatest predictive power remains to be seen when 
they are further tested in independent studies with a much larger sample size. 
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Table 1. One hundred and thirty one differentially expressed genes between OSCC and controls 
in training set (See attachment “Table 1”) 
Table 1. One hundred and thirty one differentially expressed genes between OSCC and controls in training set
Up-regulation in OSCC Down-regulation in OSCC
Probe Set Gene Z Score Probe Set Gene Z Score Probe Set Gene Z Score
202311_s_at COL1A1 22.3 212365_at MYO1B 12.0 1553212_at KRT78 -18.6
202404_s_at COL1A2 20.6 212012_at PXDN 11.9 220149_at FLJ22671 -18.1
202310_s_at COL1A1 20.3 229860_x_at LOC401115 11.8 241233_x_at C21orf81 -16.4
211980_at COL4A1 19.5 219211_at USP18 11.8 1569608_x_at LOC643187 -15.2
202267_at LAMC2 18.8 219863_at HERC5 11.8 220962_s_at PADI1 -14.5
204415_at IFI6 18.6 204619_s_at CSPG2 11.7 210868_s_at ELOVL6 -14.0
225681_at CTHRC1 18.0 203968_s_at CDC6 11.5 205319_at PSCA -13.7
212488_at COL5A1 17.0 208156_x_at EPPK1 11.5 204754_at HLF -13.7
211924_s_at PLAUR 16.8 210797_s_at OASL 11.4 218779_x_at EPS8L1 -13.5
203256_at CDH3 16.3 1568765_at SERPINE1 11.4 221665_s_at EPS8L1 -13.2
221729_at COL5A2 16.2 204972_at OAS2 11.2 220016_at AHNAK -12.8
213869_x_at THY1 15.8 223541_at HAS3 11.2 218885_s_at GALNT12 -12.7
217312_s_at COL7A1 15.7 218888_s_at NETO2 11.1 231118_at ANKRD35 -12.7
1555778_a_at POSTN 15.6 209949_at NCF2 11.1 225548_at SHROOM3 -12.1
212489_at COL5A1 15.3 204779_s_at HOXB7 11.0 206094_x_at UGT1A6 -11.9
221730_at COL5A2 15.2 41037_at TEAD4 11.0 206093_x_at TNXB -11.9
212354_at SULF1 15.1 209800_at KRT16 10.9 218935_at EHD3 -11.9
207517_at LAMC2 15.0 217519_at MACF1 10.8 207126_x_at UGT1A4 -11.8
212344_at SULF1 15.0 202238_s_at NNMT 10.7 230740_at --- -11.7
204715_at PANX1 14.7 221898_at PDPN 10.7 204532_x_at UGT1A4 -11.6
208851_s_at THY1 14.2 201108_s_at THBS1 10.7 242417_at LOC283278 -11.5
222693_at FNDC3B 13.9 209969_s_at STAT1 10.4 213421_x_at PRSS3 -10.6
204647_at HOMER3 13.9 203921_at CHST2 10.2 205200_at CLEC3B -10.5
213668_s_at SOX4 13.7 204103_at CCL4 10.2 1552283_s_at ZDHHC11 -10.4
205574_x_at BMP1 13.3 241872_at SGIP1 10.1 220037_s_at XLKD1 -10.1
1555420_a_at KLF7 13.3 207850_at CXCL3 10.0 1553861_at TCP11L2 -10.0
217430_x_at COL1A1 13.3 204747_at IFIT3 9.7 204378_at BCAS1 -9.7
210809_s_at POSTN 13.2 219725_at TREM2 9.6 242009_at --- -9.7
205157_s_at KRT17 12.9 203915_at CXCL9 9.6 207206_s_at ALOX12 -9.6
203695_s_at DFNA5 12.9 204879_at PDPN 9.6 205730_s_at ABLIM3 -9.4
203325_s_at COL5A1 12.9 1554008_at OSMR 9.3 238715_at ARHGAP27 -9.1
209900_s_at SLC16A1 12.8 204051_s_at SFRP4 9.2 205428_s_at CALB2 -8.6
203085_s_at TGFB1 12.7 227697_at SOCS3 9.1 1565661_x_at FUT6 -8.4
229225_at NRP2 12.7 210001_s_at SOCS1 9.0 208609_s_at TNXA /TNXB -8.3
225288_at --- 12.5 235276_at --- 8.5 227782_at ZBTB7C -8.3
202235_at SLC16A1 12.5 222344_at C5orf13 8.4 226303_at PGM5 -8.1
204114_at NID2 12.5 225520_at MTHFD1L 8.4 240000_at --- -8.0
229554_at --- 12.4 218404_at SNX10 8.3 201497_x_at MYH11 -7.8
214453_s_at IFI44 12.4 229055_at GPR68 8.1 227419_x_at PLAC9 -7.3
212472_at MICAL2 12.3 209774_x_at CXCL2 8.0 230104_s_at TPPP -7.2
205483_s_at ISG15 12.2 39402_at IL1B 7.2 212224_at ALDH1A1 -7.1
226997_at --- 12.2 219300_s_at CNTNAP2 6.9 243718_at --- -6.7
212473_s_at MICAL2 12.0 229947_at PI15 6.7 209975_at CYP2E1 -6.5
225292_at COL27A1 12.0 238581_at GBP5 6.3
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Table 2. Validation of predictive models using internal and external (GSE6791) testing datasets 
  Area Under the Curve 
Model with Gene Name & 
Affymetrix Probe Set ID 
 







Model 1  




7.8739*LAMC2+7.6269*COL4A1 0.99792  0.97619 
 
      





2.4377*COL1A1-2.8841*PADI1 0.99167  0.97789 
 
      
Model 3  
C21orf81, 241233_x_ 
 
-2.1042* C21orf81 0.98540  0.97450 
 
      





2.5638* KRT17-2.4506* PRSS3 0.97710  0.97450 
 
      





1.9345* COL1A2-1.5931*230740_at 0.98960  0.95920 
 
      





2.2372*COL1A1-1.3377* XLKD1 0.99170  0.95070 
 
      






2.4643* THY1-1.6340* FLJ522671 
+1.5310* HAS3 0.99790  0.96260 
 
      





1.4909* POSTN+1.8340* TIA2 0.98960  0.90820 
 
      







GIP3+1.7854* COL27A1 0.97290  0.95410 
 
      
Model 10  
CDH3, 203256_at 
ELOVL6, 210868_s_at 1.9861*CDH3-2.1743*ELOVL6 0.99380  0.89800 
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   Table 3. qRT-PCR results comparing RNA transcripts for four genes 
   between OSCC cases and controls 
  Mean (S.D.) Ct* 95% CI** p 
LAMC2     
Case  2.83 (1.02) 2.44-3.21 ≤0.0001 
Control  7.38 (0.54) 7.18-7.59  
     
COL4A1     
Case  5.13 (0.86) 4.81-5.45 ≤0.0001 
Control  8.58 (0.78) 8.29-8.87  
     
COL1A1     
Case  2.28 (1.14) 1.85-2.71 ≤0.0001 
Control  6.94 (0.64) 6.70-7.18  
     
PADI1     
Case  10.86 (2.34) 9.99-11.73 ≤0.0001 
Control  5.06 (0.94) 4.71-5.41  
   *Ct (threshold cycle) values are inversely associated with the amount  
   of RNA transcripts in the sample. Based on analyses of 30 OSCC cases  
   and 30 controls. 
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Table 4. Differentially expressed genes between OSCC and dysplasia plus normal 
controls that overlap with the 131 genes  
Up-regulation in OSCC  Down-regulation in OSCC 
Probe Set Gene 
Z 
Score  Probe Set Gene 
Z 
Score 
202267_at LAMC2 17.6  205200_at TNA -14.7 
207517_at LAMC2 17.5  231118_at FLJ25124 -14.0 
1568765_at SERPINE1 14.9  206093_x_at TNXB -13.1 
1555420_a_at KLF7 13.8  227782_at ZBTB7C -11.3 
222693_at FAD104 13.6  1552283_s_at ZDHHC11 -11.2 
207850_at CXCL3 12.8  213421_x_at PRSS3 -10.8 
210001_s_at SOCS1 11.9  238715_at ARHGAP27 -10.6 
229225_at NRP2 11.8  208609_s_at TNXB -10.4 
227697_at SOCS3 11.6  242009_at  -10.3 
209949_at NCF2 11.5  226303_at PGM5 -9.9 
204103_at CCL4 11.5  207206_s_at ALOX12 -9.7 
218404_at SNX10 11.4  230104_s_at TPPP -9.6 
203695_s_at DFNA5 11.4  220037_s_at XLKD1 -8.6 
212354_at SULF1 11.2  243718_at  -8.6 
229860_x_at LOC4115 10.9  227419_x_at PLAC9 -8.5 
209774_x_at CXCL2 10.8  201497_x_at MYH11 -8.0 
241872_at SGIP1 10.7  204532_x_at UGT1A10 -7.8 
203968_s_at CDC6 10.6  206094_x_at UGT1A1,1A4,1A6 -7.6 
225520_at FTHFSDC1 10.1  207126_x_at UGT1A10 -7.5 
229947_at PI15 9.3  212224_at ALDH1A1 -6.4 
204747_at IFIT3 8.9     
39402_at IL1B 8.9     
235276_at EPSTI1 8.8     
203915_at CXCL9 8.7     
204779_s_at HOXB7 8.6     
219211_at USP18 8.5     
238581_at GBP5 7.6     
219300_s_at CNTNAP2 5.0     
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Figure 1 (See attachment “Figure 1”) 
Legend for Figure 1: 
Figure 1. Most prominently involved biological pathways in OSCC. Top: JAK/STAT pathway. 
Bottom: IFN-γ signaling pathway, antigen-presenting pathway. Red denotes up-regulation and 


























Figure 2. Tissue specificity of model LAMC2 and COL4A1 (top) and model COL1A1 and PADI1 
(bottom). Box Whisker plots of logistic regression scores (y axis) for normal controls and cases 
in our own testing set (N: normal, DYS: dysplasia, T: OSCC), GEO GSE6791 head and neck 
normal controls (HN N) and cases (HN T), GEOGSE 6791 cervical normal controls (C N)and 
cases (C T), and GEO GSE6044 lung normal controls (L N), lung squamous cell carcinoma (L 
SCC), lung adenocarcinoma (L AD) and lung small cell cancer (L SC). 
 
